Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 "ASPECT-2"

Completed

Phase N/A Results

Trial Description

To determine the long term efficacy of aspirin and oral anticoagulants in reducing ischemic events after acute coronary events.

Interventions

Trial Design

Prospective, multicenter, randomized open-label trial.

Patient Involvement

Patients were randomized into 3 groups to receive either aspirin (80 mg) (n=336), oral anticoagulants (target INR 3.0-4.0) (n=325) or oral anticoagulants (target INR 2.0-2.50 plus aspirin (80 mg) (n=332). An assessment questionnaire was completed every 3 months.

Outcomes

Type Measure Time Frame Safety Issue
Primary Death, time to myocardial infarction or stroke.
Secondary Death from all causes, episodes of bleeding.

Sponsors

The Netherlands National Health Insurance Fund Council